Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02701634

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Clinical Trial Summary

The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids as part of first-line therapy for cGVHD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02701634
Study type Interventional
Source Gilead Sciences
Contact
Status Terminated
Phase Phase 2
Start date May 27, 2016
Completion date March 6, 2018
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Terminated NCT02337517 - Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02461134 - Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD Phase 2
Recruiting NCT03839069 - Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis N/A
Active, not recruiting NCT00637689 - Improving Outcomes Assessment in Chronic GVHD
Not yet recruiting NCT06233110 - Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD Phase 1
Active, not recruiting NCT01937468 - Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 1
Completed NCT01380535 - Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) Early Phase 1
Completed NCT01810718 - Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD Phase 1
Terminated NCT01964625 - Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD) N/A
Active, not recruiting NCT03790332 - Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) Phase 1/Phase 2
Completed NCT01680965 - Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Phase 1/Phase 2
Completed NCT02491359 - Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Phase 2
Recruiting NCT06300320 - A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease Phase 2
Recruiting NCT05922761 - BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Phase 2
Recruiting NCT06247150 - Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD) N/A
Active, not recruiting NCT04212416 - Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Phase 1
Completed NCT02959944 - Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) Phase 3
Completed NCT01954979 - Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Phase 1
Active, not recruiting NCT04640025 - A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib Phase 2